Anti-CD38 Antibody Depletion of IgE-Producing B Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective treatment options for IgE-mediated diseases such as allergies and autoimmune disorders, as current treatments are limited and often require strict allergen avoidance, with no curative solutions and potential for accidental reactions leading to severe health issues.

Innovation Solution

Administering an antibody that specifically binds CD38 to reduce total IgE and allergen-specific IgE levels in subjects, targeting B cells expressing and secreting IgE.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for IgE-mediated diseases are used, then symptom management is achieved, but curative treatment is not available and strict allergen avoidance is required

Engineering Contradiction:

Improvecurative treatment availabilityVSAvoidallergen avoidance requirements

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent extracts and targets the root cause of IgE-mediated diseases by specifically binding to CD38 on IgE-producing plasma cells, extracting these pathogenic cells from the system through antibody-mediated depletion, thereby achieving curative treatment without requiring allergen avoidance

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The anti-CD38 antibody serves as an intermediary that mediates the destruction of IgE-producing plasma cells through immune mechanisms (ADCC, ADCP, CDC), enabling curative treatment by eliminating the source of pathogenic IgE without direct patient intervention or allergen avoidance

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If IgE levels are reduced through antibody treatment, then therapeutic benefits are achieved, but the mechanism targets B cells expressing and secreting IgE

Engineering Contradiction:

ImproveIgE levelsVSAvoidtargeting mechanism complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent changes the target parameter from IgE itself to CD38 on the surface of IgE-producing plasma cells, enabling effective reduction of IgE levels through antibody-mediated cell depletion while maintaining relatively simple treatment administration

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The anti-CD38 antibody acts as an intermediary that indirectly reduces IgE levels by targeting and depleting the plasma cells that produce IgE, achieving the desired reduction in IgE quantity through a mediating mechanism rather than direct IgE binding

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibody effectively decreases IgE levels over time, providing therapeutic benefits for IgE-mediated diseases by reducing symptoms and potentially preventing severe allergic reactions.

Implementation Method 1

an antibody that specifically binds CD38 for a time sufficient to treat the IgE-mediated disease

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS12528878B2Treatment of IgE-mediated diseases with antibodies that specifically bind CD38

Publication Date: 2026.01.20 UMC UTRECHT HLDG BV

AI summary

The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.